Hemoglobin Clinical Trials

60 recruitingLast updated: July 25, 2026

There are 60 actively recruiting hemoglobin clinical trials across 47 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable, Early Phase 1. Top locations include Seoul, South Korea, Minneapolis, Minnesota, United States, New York, New York, United States. Updated daily from ClinicalTrials.gov.


Hemoglobin Trials at a Glance

60 actively recruiting trials for hemoglobin are listed on ClinicalTrialsFinder across 6 cities in 47 countries. The largest study group is Phase 2 with 19 trials, with the heaviest enrollment activity in Seoul, Minneapolis, and New York. Lead sponsors running hemoglobin studies include Novartis Pharmaceuticals, Masonic Cancer Center, University of Minnesota, and National Heart, Lung, and Blood Institute (NHLBI).

Browse hemoglobin trials by phase

Treatments under study

About Hemoglobin Clinical Trials

Looking for clinical trials for Hemoglobin? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hemoglobin trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hemoglobin clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 60 trials

Recruiting

Danicopan PMS in Korea

Paroxysmal nocturnal hemoglobinuria
AstraZeneca8 enrolled4 locationsNCT07457151
Recruiting
Phase 3

A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works

Paroxysmal nocturnal hemoglobinuria
Regeneron Pharmaceuticals202 enrolled45 locationsNCT05744921
Recruiting
Phase 1Phase 2

A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor

Paroxysmal Nocturnal Hemoglobinuria, PNHPersistent Anemia
Regeneron Pharmaceuticals24 enrolled8 locationsNCT07187401
Recruiting
Phase 3

A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently

Paroxysmal nocturnal hemoglobinuria
Regeneron Pharmaceuticals35 enrolled19 locationsNCT07154745
Recruiting
Phase 1

Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease

Sickle Cell DiseaseHb-SS DiseaseHemoglobin S+3 more
National Heart, Lung, and Blood Institute (NHLBI)25 enrolled1 locationNCT05904093
Recruiting
Not Applicable

Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

HemoglobinopathiesImmunodeficienciesHematologic Disorders
Masonic Cancer Center, University of Minnesota30 enrolled1 locationNCT01666080
Recruiting
Phase 2

Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis

Paroxysmal Nocturnal Hemoglobinuria, PNHSevere Aplastic Anemia (SAA)Hypo-Plastic Myelodysplastic Syndrome (MDS)
National Heart, Lung, and Blood Institute (NHLBI)56 enrolled1 locationNCT03520647
Recruiting

A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal nocturnal hemoglobinuria
Swedish Orphan Biovitrum200 enrolled87 locationsNCT05776472
Recruiting
Phase 2

TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children

Severe Aplastic AnemiaHemoglobinopathy (Disorder)Bone Marrow Failure Syndrome
Johns Hopkins All Children's Hospital17 enrolled1 locationNCT04356469
Recruiting

A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy

C3 GlomerulopathyParoxysmal nocturnal hemoglobinuria
Novartis Pharmaceuticals21 enrolled3 locationsNCT07416162
Recruiting

Transfusion-Related Changes in Oxidative Stress Biomarkers in Neonates

Fetal HemoglobinNear-Infrared SpectroscopyOxidative Stress in Neonates+1 more
Medical University of Graz170 enrolled1 locationNCT07672275
Recruiting
Phase 2

A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria, PNHParoxysmal Hemoglobinuria
Apellis Pharmaceuticals, Inc.12 enrolled12 locationsNCT04901936
Recruiting

REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria, PNH
Novartis Pharmaceuticals50 enrolled12 locationsNCT07229235
Recruiting
Phase 1Phase 2

Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

Paroxysmal Nocturnal Hemoglobinuria, PNH
ADARx Pharmaceuticals, Inc.50 enrolled4 locationsNCT05876312
Recruiting

The HOPE Biobank Resource (BMT CTN 2402 HOPE)

Bone Marrow FailureHemoglobinopathiesAplastic Anemias
Medical College of Wisconsin375 enrolled6 locationsNCT07227155
Recruiting
Phase 1

131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)

Sickling Disorder Due to Hemoglobin S
Columbia University24 enrolled1 locationNCT07015684
Recruiting
Phase 2

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Severe Aplastic AnemiaAcquired Amegakaryocytic ThrombocytopeniaAcquired Pure Red Cell Aplasia+1 more
Masonic Cancer Center, University of Minnesota60 enrolled1 locationNCT06412497
Recruiting
Phase 2

Allo HSCT for High Risk Hemoglobinopathies

Sickle Cell DiseaseHemoglobinopathiesGraft Failure
Masonic Cancer Center, University of Minnesota62 enrolled1 locationNCT06872333
Recruiting

A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China

Paroxysmal nocturnal hemoglobinuria
Novartis Pharmaceuticals80 enrolled14 locationsNCT06931691
Recruiting
Phase 1Phase 2

Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

HemoglobinopathiesBone Marrow Failure SyndromesMetabolic Disorders+3 more
Washington University School of Medicine29 enrolled4 locationsNCT03128996